UK's Advanced Medical Solutions 2025 revenue rises 29% on acquisitions growth

Advanced Medical Solutions

18/03/2026 07:12

Overview

UK tissue-healing device maker's preliminary 2025 revenue rose 29% on organic growth and acquisitions

Adjusted EBITDA for 2025 rose 24%, with adjusted diluted EPS up 12% year-over-year

Company proposed a 10% increase in full-year dividend, citing confidence in outlook

Outlook

AMS expects 2026 revenue of £245.3 mln and adjusted EBITDA of £55.2 mln

Company expects continued strong growth in Surgical and modest growth in Woundcare

AMS anticipates multiple product approvals from 2026 onwards across adhesives, sutures and collagen technologies

Result Drivers

ACQUISITION IMPACT - Full-year contribution from Peters Surgical and Syntacoll acquisitions drove revenue growth and expanded product portfolio

SURGICAL UNIT GROWTH - Strong performance in adhesives, biosurgical devices, and sutures underpinned results, with notable gains in the US and APAC regions

WOUNDCARE RECOVERY - Woundcare business returned to growth after restructuring, supported by new supply agreements and focus on higher-margin products

Company press release: ID:nRSR1189Xa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted EPS
GBP 0.12
FY EPS
GBP 0.05
FY Adjusted Pretax Profit
GBP 33.90 mln
FY Pretax Profit
GBP 17.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Advanced Medical Solutions Group PLC is GBp275.00, about 39.7% above its March 17 closing price of GBp196.80

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)